IL-33 protects against atherosclerosis: the number of atherosclerotic plaques was significantly lower in the IL-33 treated ApoE−/− mice compared to the control, phosphate-buffered saline-treated group; additionally, mice receiving soluble ST2 (sST2), an IL-33 neutralizing decoy receptor, developed more extensive aortic sinus atherosclerosis compared to ApoE−/− mice solely injected with the control IgG [101]. Here, IL33 is linked to atherosclerosis.